Cargando…

Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma

BACKGROUND: Chemotherapeutic options for the treatment of canine lymphoma have not changed in several decades necessitating the identification of new therapeutics to improve patient outcome. KPT-335 (verdinexor) is a novel orally bioavailable selective inhibitor of nuclear export (SINE) that exhibit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sadowski, Abbey R., Gardner, Heather L., Borgatti, Antonella, Wilson, Heather, Vail, David M., Lachowicz, Joshua, Manley, Christina, Turner, Avenelle, Klein, Mary K., Waite, Angharad, Sahora, Alexandra, London, Cheryl A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109271/ https://www.ncbi.nlm.nih.gov/pubmed/30143046 http://dx.doi.org/10.1186/s12917-018-1587-9

Ejemplares similares

Preclinical Evaluation of the Novel, Orally Bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Spontaneous Canine Cancer: Results of a Phase I Study
por: London, Cheryl A., et al.
Publicado: (2014)

Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines
por: Breit, Megan N, et al.
Publicado: (2014)

The selective inhibitor of nuclear export (SINE) verdinexor exhibits biologic activity against canine osteosarcoma cell lines
por: Breitbach, Justin T., et al.
Publicado: (2021)

Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185
por: Tabe, Yoko, et al.
Publicado: (2015)

The SINE Compound KPT-350 Blocks Dystrophic Pathologies in DMD Zebrafish and Mice
por: Hightower, Rylie M., et al.
Publicado: (2020)

Next-Generation SINE Compound KPT−8602 Ameliorates Dystrophic Pathology in Zebrafish and Mouse Models of DMD
por: English, Katherine G., et al.
Publicado: (2022)

Selective nuclear export inhibitor KPT‑330 enhances the radiosensitivity of esophageal carcinoma cells
por: Xu, Jing, et al.
Publicado: (2023)

Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells
por: Uddin, Md. Hafiz, et al.
Publicado: (2021)

Selective inhibitors of nuclear export (SINE) in hematological malignancies
por: Das, Arundhati, et al.
Publicado: (2015)

Safety and toxicity of combined oclacitinib and carboplatin or doxorubicin in dogs with solid tumors: a pilot study
por: Barrett, Laura E., et al.
Publicado: (2019)

KPT330 improves Cas9 precision genome- and base-editing by selectively regulating mRNA nuclear export
por: Cui, Yan-ru, et al.
Publicado: (2022)

Antiviral Efficacy of Verdinexor In Vivo in Two Animal Models of Influenza A Virus Infection
por: Perwitasari, Olivia, et al.
Publicado: (2016)

Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer
por: Mendonca, Janet, et al.
Publicado: (2014)

Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses
por: Pickens, Jennifer A., et al.
Publicado: (2018)

In vitro toxicity and efficacy of verdinexor, an exportin 1 inhibitor, on opportunistic viruses affecting immunocompromised individuals
por: Widman, Douglas G., et al.
Publicado: (2018)

Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agents
por: Parikh, Kaushal, et al.
Publicado: (2014)

Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds
por: Crochiere, Marsha, et al.
Publicado: (2015)

Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma
por: Garg, Manoj, et al.
Publicado: (2016)

Give me a SINE: how Selective Inhibitors of Nuclear Export modulate autophagy and aging
por: Kumar, A.V., et al.
Publicado: (2018)

KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells
por: Etchin, J, et al.
Publicado: (2017)

SINE (selective inhibitor of nuclear export) – translational science in a new class of anti-cancer agents
por: Gerecitano, John
Publicado: (2014)

XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor
por: Pan, Lijia, et al.
Publicado: (2021)

A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds
por: Crochiere, Marsha L., et al.
Publicado: (2015)

Genome-wide mapping of infection-induced SINE RNAs reveals a role in selective mRNA export
por: Karijolich, John, et al.
Publicado: (2017)

KPT-330 has antitumour activity against non-small cell lung cancer
por: Sun, H, et al.
Publicado: (2014)

Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19-positive malignancies
por: Wang, Sanmei, et al.
Publicado: (2021)

A Phase II Trial of Selinexor (KPT‐330) for Metastatic Triple‐Negative Breast Cancer
por: Shafique, Michael, et al.
Publicado: (2019)

KPT6566 induces apoptotic cell death and suppresses the tumorigenicity of testicular germ cell tumors
por: Sun, Ruijing, et al.
Publicado: (2023)

MetaSINEs: Broad Distribution of a Novel SINE Superfamily in Animals
por: Nishihara, Hidenori, et al.
Publicado: (2016)

The sine transform is the sine qua non of the pulmonary and systemic pressure relationship
por: Doyle, Mark, et al.
Publicado: (2023)

Sine nomine Kein firmanent /
por: Rihm, Wolfgang
Publicado: (1992)

Health Tract No. 335: Eyesight
Publicado: (1868)

The remarkable sine functions
por: Markushevich, A I
Publicado: (1966)

SINEs create boundaries
por: Powell, Kendall
Publicado: (2007)

Ipecacuanha Sine Emetina
por: Kanthack, A. A., et al.
Publicado: (1894)

Amœbiasis Sine Dysentery
Publicado: (1942)

Ipecacuanha Sine Emetfna
por: Tull-Walsh, J. H.
Publicado: (1893)

KPT-330 inhibition of chromosome region maintenance 1 is cytotoxic and sensitizes chronic myeloid leukemia to Imatinib
por: Nie, Danian, et al.
Publicado: (2018)

Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer
por: Arango, Natalia Paez, et al.
Publicado: (2017)

Verdinexor, a Selective Inhibitor of Nuclear Exportin 1, Inhibits the Proliferation and Migration of Esophageal Cancer via XPO1/c-Myc/FOSL1 Axis
por: Ou, Ling, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_44h1rg5rcj4it74jhunftqh1ql